uniQure (NASDAQ:QURE) Trading 8.6% Higher – Here’s What Happened

uniQure N.V. (NASDAQ:QURE)’s stock price was up 8.6% during trading on Monday . The company traded as high as $24.42 and last traded at $24.6630. Approximately 788,212 shares traded hands during mid-day trading, a decline of 57% from the average daily volume of 1,823,675 shares. The stock had previously closed at $22.72.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Stifel Nicolaus reduced their price target on uniQure from $50.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, December 11th. Cantor Fitzgerald restated an “overweight” rating on shares of uniQure in a research note on Wednesday, January 14th. Leerink Partners dropped their target price on uniQure from $68.00 to $60.00 and set an “outperform” rating on the stock in a report on Monday, November 10th. Benchmark reaffirmed a “buy” rating on shares of uniQure in a report on Tuesday, November 4th. Finally, Chardan Capital reissued a “buy” rating and set a $53.00 target price on shares of uniQure in a research note on Thursday, December 4th. Ten equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $58.33.

uniQure Stock Up 8.7%

The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.23. The business has a fifty day simple moving average of $23.63 and a two-hundred day simple moving average of $28.53. The company has a market cap of $1.54 billion, a PE ratio of -5.63 and a beta of 0.68.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.53). The business had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $4.46 million. uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%. As a group, equities research analysts predict that uniQure N.V. will post -3.75 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Jack Kaye sold 6,390 shares of the business’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $27.28, for a total transaction of $174,319.20. Following the completion of the transaction, the director directly owned 20,439 shares of the company’s stock, valued at approximately $557,575.92. The trade was a 23.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Robert Gut sold 25,613 shares of the stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $24.62, for a total value of $630,592.06. Following the completion of the transaction, the director owned 32,342 shares in the company, valued at approximately $796,260.04. The trade was a 44.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 102,247 shares of company stock worth $2,839,298 in the last 90 days. Company insiders own 4.79% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Woodline Partners LP boosted its position in uniQure by 25.0% during the first quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after purchasing an additional 35,175 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in uniQure in the 2nd quarter valued at approximately $117,000. Aberdeen Group plc boosted its stake in shares of uniQure by 24.2% during the second quarter. Aberdeen Group plc now owns 2,750,714 shares of the biotechnology company’s stock valued at $38,345,000 after acquiring an additional 535,163 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in uniQure during the 2nd quarter worth about $872,000. Finally, Teacher Retirement System of Texas acquired a new position in uniQure in the 2nd quarter valued at about $151,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.